Related Experiment Video
Updated: Sep 20, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity
K Gołembiowska1, J Konieczny, S Wolfarth
1Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Cracow, Poland.
Abstract:
The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats. Methamphetamine (10 mg/kg sc), administered five times, reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection. A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects. A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM). Moreover, it transiently diminished the methamphetamine (10 mg/kg sc)-induced hyperthermia and reduced basal body temperature. MPEP administered into the striatum at high concentrations (500 microM) increased extracellular dopamine levels, while lower concentrations (50-100 microM) were devoid of any effect. The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity. Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.
Insights
The metabotropic glutamate receptor 5 (mGluR5) antagonist MPEP protected rat dopaminergic neurons from methamphetamine toxicity. MPEP reduced methamphetamine-induced dopamine release and hyperthermia, suggesting a neuroprotective role.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Methamphetamine (METH) causes neurotoxicity to dopaminergic neurons.
- Metabotropic glutamate receptor 5 (mGluR5) is implicated in neuronal function and drug effects.
Purpose of the Study:
- To investigate the role of mGluR5 in methamphetamine-induced dopaminergic neurotoxicity in rats.
- To evaluate the neuroprotective potential of an mGluR5 antagonist against methamphetamine effects.
Main Methods:
- Rats received repeated methamphetamine injections, and striatal dopamine/metabolite levels were measured.
- An mGluR5 antagonist, MPEP, was administered before methamphetamine to assess its effects.
- Extracellular dopamine levels, dopamine release, and body temperature were monitored following MPEP administration.
Main Results:
- Methamphetamine reduced striatal dopamine and metabolite levels.
- MPEP administration reversed methamphetamine-induced dopamine depletion.
- MPEP reduced methamphetamine-stimulated dopamine release and hyperthermia, but high intrastriatal MPEP increased dopamine.
Conclusions:
- Blockade of mGluR5 by MPEP demonstrates neuroprotective effects against methamphetamine toxicity in dopaminergic neurons.
- MPEP's neuroprotection may involve reducing METH-induced dopamine efflux and hyperthermia.
- Targeting mGluR5 offers a potential therapeutic strategy for methamphetamine-induced neurotoxicity.
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Drugs Affecting Neurotransmitter Release or Uptake
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...